Delving into the Latest Updates on Shenzhen Simnova Biotechnology Co.,Ltd. with Synapse

Overview

Tags

Neoplasms

Hemic and Lymphatic Diseases

Immune System Diseases

in vivo CAR-T therapy

CAR-T

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	11
Hemic and Lymphatic Diseases	4
Immune System Diseases	4
Nervous System Diseases	1

Top 5 Drug Type	Count

CAR-NK	5
CAR-T	3
Autologous CAR-T	1
Fusion protein	1
in vivo CAR-T therapy	1

Top 5 Target	Count

CD19(B-lymphocyte antigen CD19)	2
BCMA(B-cell maturation protein)	2
EGFRvIII x HER2 x IL-13Rα2	1
DLL3(Delta-like protein 3)	1
BCMA x GPRC5D	1

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 14 May 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

3

2

Preclinical

IND Approval

1

2

Phase 1

Phase 2

2

7

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

SNC-102 ( BCMA )	Multiple Myeloma More	Phase 2
SNC110	Solid tumor More	Phase 2
SNC-103 ( CD19 )	Systemic Lupus Erythematosus More	Phase 1
SNC-109 ( EGFRvIII x HER2 x IL-13Rα2 )	Glioblastoma Multiforme More	Phase 1
SNC-112 ( BCMA x GPRC5D )	Multiple Myeloma More	Preclinical